24-May-2011 - MediGene AG

MediGene Signs Veregen Commercialization Agreement with SynCore Bio in Taiwan

MediGene AG  has signed an exclusive license and supply agreement with SynCore Bio, a subsidiary of the Sinphar Group, for the commercialization and marketing of Veregen® ointment in Taiwan for the treatment of genital warts. MediGene will supply Sinphar with API, Sinphar will produce the drug in its Taiwan manufacturing facilities and SynCore Bio will market and sell the ointment in Taiwan. Financial details of the agreement were not disclosed.

Facts, background information, dossiers
  • Taiwan
  • Medigene
  • genital warts
  • Veregen
More about MediGene
  • News

    Medigene announces change in executive leadership team

    Medigene AG announced that the Chief Financial Officer (CFO), Dr. Thomas Taapken, will leave the Company for personal reasons and will resign from his CFO position effective August 31, 2018. His departure is not based on any disagreement with the Company's accounting principles or practices ... more

    Medigene appoints new CMO/CDO

    Medigene AG announcedthe appointment of Dr. Kai Pinkernell to the Executive Management Board of the Company as Chief Medical Officer (CMO) and Chief Development Officer (CDO). Dr. Pinkernell has been with Medigene as Senior Vice President and Chief Medical Officer (CMO) since February 2016. ... more

    Medigene announces formation of new Scientific Advisory Board

    Medigene AG announced the appointment of eight leading experts to its new immuno-oncology-focused Scientific Advisory Board (SAB). The SAB will consult the company with regard to strategic options and future perspectives within its research and development activities. The SAB will thereby f ... more